Roche’s Xofluza Receives the EC’s Approval for the Treatment of Influenza

January 11, 2021 Auto Bot approval, EC, influenza, receives, regulatory, Roche, Xofluza 0

Shots:

  • The EC has approved Xofluza (baloxavir marboxil) for uncomplicated influenza in patients aged≥12yrs. Additionally, the EC has approved Xofluza for post-exposure prophylaxis of influenza in individuals aged≥12yrs.
  • The approval follows the CHMP’s positive opinion for Xofluza and is based on P-III CAPSTONE-1, CAPSTONE-2 and BLOCKSTONE studies
  • Xofluza is a first-in-class, single-dose oral therapy, reduces the societal burden of influenza with a rapid reduction in viral replication

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Krauthammer

The post Roche’s Xofluza Receives the EC’s Approval for the Treatment of Influenza first appeared on PharmaShots.